Clinical Thyroidology® for the Public

Summaries for the Public from recent articles in Clinical Thyroidology
Table of Contents | PDF File for Saving and Printing

THYROID IN PREGNANCY
2026 American Thyroid Association guidelines for thyroid disease in pregnancy: Hypothyroidism

Instagram Youtube LinkedIn Facebook X

 

BACKGROUND
Thyroid hormone plays a major role in brain development of the baby during pregnancy. During the 1st trimester, all the thyroid hormone that the baby gets comes from the mother. After that, the baby’s thyroid starts working, but the baby still needs some thyroid hormone from the mother. Hypothyroidism is common in women who are pregnant or are planning pregnancy. While overt hypothyroidism (high TSH and low FT4) clearly requires treatment with levothyroxine, it is less clear that subclinical hypothyroidism (High TSH, normal FT4) needs to be treated. Because some studies have associated hypothyroidism in the mother with miscarriage, preterm birth, and impaired brain development in the baby, doctors have traditionally had a low threshold for starting levothyroxine treatment. However, the evidence has changed substantially since the 2017 American Thyroid Association (ATA) guidelines. Trials of treatment for subclinical hypothyroidism have highlighted the importance of timing during pregnancy and the possibility of overtreatment. Further, trials treating pregnant women with normal thyroid levels but positive TPO antibodies have generally failed to show any benefit.

The 2026 ATA guidelines represent a meaningful shift from reflex treatment toward confirming persistent hypothyroidism and individualized decision-making. The key aspects in the section on hypothyroidism have been outlined here.

THE FULL ARTICLE TITLE
Korevaar TIM, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid 2026;36(5):481–544; doi: 10.1177/10507256261445624. PMID: 42219800.

SUMMARY OF THE STUDY
The 2026 ATA guidelines on hypothyroidism in pregnancy outlines recommendations depending on the timing (prior to pregnancy or during pregnancy) and the degree of hypothyroidism (subclinical or over hypothyroidism).

In individuals with subclinical hypothyroidism, it is suggested that TPO antibody status is not required to guide the decision to treat. Levothyroxine therapy may be considered for persistent subclinical hypothyroidism prior to pregnancy or during the first trimester of pregnancy.

Studies have not demonstrated improvement in the risk of pregnancy related complications or brain development of the child with starting levothyroxine after the first trimester for subclinical hypothyroidism. It is also suggested to repeat testing for confirmation of subclinical hypothyroidism (or for mild overt hypothyroidism with TSH <6 mU/L) prior to starting levothyroxine therapy as a significant proportion of patients may have normalization of their TSH levels on repeat testing. If treatment is started, low doses of levothyroxine (25 to 75 mcg) should be considered to avoid over replacement.

With regards to overt hypothyroidism, the guidelines recommend treating an established diagnosis prior to pregnancy. The goal treatment target is a TSH in the normal range; however a TSH less than 2.5 mU/L can be targeted to create a safety margin for remaining in the normal range during pregnancy. Individuals using liothyronine (T3) or desiccated thyroid preparations (which contain T3 as well as T4) are recommended to switch to levothyroxine only to avoid the risk of insufficient thyroid hormone availability to the developing baby.

Similarly, overt hypothyroidism identified during pregnancy, particularly with a TSH of 6 mU/L or higher, is an indication for initiation of levothyroxine. Most individuals on levothyroxine for overt hypothyroidism will require an increase in the dose (by approximately 25% and 50% by weeks 12 and 20 respectively) to maintain thyroid hormone levels in the normal range. Finally, following delivery levothyroxine can be switched back to the prepregnancy dose and thyroid function checked after six weeks.

WHAT ARE THE IMPLICATIONS OF THIS STUDY?
Compared to the prior guideline published in 2017, the 2026 guideline predominantly retains the same key approaches to the management of hypothyroidism with a few exceptions. While TPO antibody levels can be helpful in identifying the cause of thyroid hormone abnormalities, it is no longer used for treatment decisions in patients who have normal thyroid function or subclinical hypothyroidism. Another difference is that the current guideline emphasizes retesting mild elevation in TSH levels prior to initiation of levothyroxine to avoid over treatment.

Shared decision making between the patient and the treating provider is important to help patients navigate the management of hypothyroidism during pregnancy with the goal to treat appropriately and to avoid over treatment and treatment related anxiety.

— Poorani Goundan, MD

ABBREVIATIONS & DEFINITIONS

Hypothyroidism: a condition where the thyroid gland is underactive and doesn’t produce enough thyroid hormone. Treatment requires taking thyroid hormone pills.

Subclinical Hypothyroidism: a mild form of hypothyroidism where the only abnormal hormone level is an increased TSH. There is controversy as to whether this should be treated or not.

Overt Hypothyroidism: clear hypothyroidism an increased TSH and a decreased T4 level. All patients with overt hypothyroidism are usually treated with thyroid hormone pills.

TPO antibodies: these are antibodies that attack the thyroid instead of bacteria and viruses, they are a marker for autoimmune thyroid disease, which is the main underlying cause for hypothyroidism and hyperthyroidism in the United States.

Levothyroxine (T4): the major hormone produced by the thyroid gland and available in pill form as Synthroid™, Levoxyl™, Tyrosint™ and generic preparations.

Thyroid hormone therapy: patients with hypothyroidism are most often treated with Levothyroxine in order to return their thyroid hormone levels to normal. Replacement therapy means the goal is a TSH in the normal range and is the usual therapy.

Desiccated thyroid extract: thyroid hormone pill made from animal thyroid glands. Currently desiccated thyroid extract is made from pig thyroids and is available as Armour Thyroid™ and Nature-Throid™.

Triiodothyronine (T3): the active thyroid hormone, usually produced from thyroxine, available in pill form as liothyronine or Cytomel™.es of the thyroid (Thyroid Scan) or to take pictures of the whole body to look for thyroid cancer (Whole Body Scan).